DepoCyt
information and resources from the National Cancer Institute
cytarabine liposomal
Accel. Approv. (clinical benefit not established) Intrathecal therapy of lymphomatous meningitis
Skye Pharmaceuticals Apr 01 1999
|
|
|
|
news articles
Enzon reports substantial loss Feb 28, 2006
MarketWatch Enzon said that it now sees its four leading products--- Abelcet, Adagen, Depocyt and Oncaspar -- having combined 2006 revenues of greater than $100 million, vs ...
Enzon to Present at Cowen 26th Annual Health Care Conference Mar 3, 2006
Genetic Engineering News, ...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ADAGEN(R), DEPOCYT(R), and ONCASPAR(R) in North America. In ...
Enzon to Present at Cowen 26th Annual Health Care Conference Mar 3, 2006
Finanzen.net, ...of therapeutics totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ADAGEN(R),DEPOCYT(R), and ...
SkyePharma defeats shareholder revolt Mar 10, 2006
Pharma Times (subscription), ...pulmonary drug delivery businesses, and try to find a buyer for San Diego-based injectables unit, which has two marketed products - DepoCyt (cytarabine) for ...
‘Running The Business’ Now Again Focus For SkyePharma Mar 14, 2006
BioWorld Online (subscription), There are two marketed products: DepoCyt, a cancer treatment, and Depodur, a controlled-release formulation of morphine for postoperative pain. ...
Enzon Reports Second Quarter Results and Transitions to Calendar ... Feb 28, 2006
Finanzen.net, ...segmentfor 2006. This segment is currently comprised of its four marketedproducts, ONCASPAR, DEPOCYT, ABELCET and ADAGEN. In 2006 ...
Enzon Reports Second Quarter Results and Transitions to Calendar ... Feb 28, 2006
Genetic Engineering News, ...segment for 2006. This segment is currently comprised of its four marketed products, ONCASPAR, DEPOCYT, ABELCET and ADAGEN. In 2006 ...
Enzon and Micromet End Research Collaboration Nov 28, 2005
Business Wire (press release), ...threatening diseases. Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R), ADAGEN(R), and DEPOCYT(R) in North America. In ...
Enzon and Micromet End Research Collaboration Nov 28, 2005
Finanzen.net, ...totreat patients with cancer and other life-threatening diseases.Enzon's specialized sales force markets ABELCET(R), ONCASPAR(R),ADAGEN(R), and DEPOCYT(R) in ...
Enzon and Micromet End Research Collaboration Nov 28, 2005
Biotech Intelligence (press release), ...threatening diseases. Enzon's specialized sales force markets ABELCET®, ONCASPAR®, ADAGEN®, and DEPOCYT® in North America. In ...
|
|
